Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs

A major complication of hemophilia A therapy is the development of alloantibodies (inhibitors) that neutralize intravenously administered coagulation factor VIII (FVIII). Immune tolerance induction therapy (ITI) by repetitive FVIII injection can eradicate inhibitors, and thereby reduce morbidity and...

Full description

Bibliographic Details
Main Authors:	Janine Becker-Gotot, Mirjam Meissner, Vadim Kotov, Blanca Jurado-Mestre, Andrea Maione, Andreas Pannek, Thilo Albert, Chrystel Flores, Frank A. Schildberg, Paul A. Gleeson, Birgit M. Reipert, Johannes Oldenburg, Christian Kurts
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2022-11-01
Series:	The Journal of Clinical Investigation
Subjects:	Hematology Immunology
Online Access:	https://doi.org/10.1172/JCI159925

Similar Items

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
by: Christian Lubich, et al.
Published: (2022-10-01)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
by: Sajjad Afraz, et al.
Published: (2022-11-01)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
by: Jin Jea Sung, et al.
Published: (2019-04-01)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014-03-01)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
by: Cansu Hemşinlioğlu, et al.
Published: (2023-06-01)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
by: Louise H Hooimeijer MD, et al.
Published: (2023-03-01)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
by: Hassan Abolghasemi, MD, et al.
Published: (2018-06-01)

Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A
by: Rou Xiao, et al.
Published: (2024-03-01)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
by: Daniel P. Hart
Published: (2020-07-01)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
by: Chao Lien Liu, et al.
Published: (2016-06-01)

The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia
by: Yingzi Zhen, et al.
Published: (2024-12-01)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
by: Yuanhua Cai, et al.
Published: (2020-06-01)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
by: Nadia El-Akabawy, et al.
Published: (2020-06-01)

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
by: Alina-Andreea Zimta, et al.
Published: (2021-04-01)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
by: Marcos V. Ferreira, et al.
Published: (2023-05-01)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022-11-01)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
by: Allison M Lytle, et al.
Published: (2016-01-01)

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
by: Ilja Oomen, et al.
Published: (2024-02-01)

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
by: Oomen, I, et al.
Published: (2024)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
by: Shuichi Okamoto, et al.
Published: (2019-10-01)

Rapid protection against viral infections by chemokine-accelerated post-exposure vaccination
by: Annkristin Heine, et al.
Published: (2024-01-01)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
by: K. Huang, et al.
Published: (2022-06-01)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
by: Chia-Yau Chang, et al.
Published: (2023-03-01)

Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
by: Matteo Nicola Dario Di Minno, et al.
Published: (2020-04-01)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
by: Kearney S, et al.
Published: (2019-04-01)

FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group
by: Chozie, Novie Amelia, et al.
Published: (2022)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4+ T-effector responses to multiple epitopes in FVIII
by: Devi Gunasekera, et al.
Published: (2023-03-01)

Bioengineering coagulation factors for improved hemophilia treatments : Comment on: the mutation F309S increases FVIII secretion in human cell line
by: Bidossessi Wilfried Hounkpe, et al.

QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC
by: L Loureiro, et al.
Published: (2023-10-01)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
by: Muhammad Elnaggar, et al.
Published: (2020-06-01)

Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCs
by: Liyan Qiu, et al.
Published: (2021-02-01)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
by: Laura H. Bukkems, et al.
Published: (2023-05-01)

ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECs
by: Zhiqing Hu, et al.
Published: (2019-09-01)

An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII.
by: Behnaz Pezeshkpoor, et al.
Published: (2017-01-01)

Combination of <i>CLEC4M</i> rs868875 G-Carriership and <i>ABO</i> O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients
by: Barbara Lunghi, et al.
Published: (2022-01-01)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study
by: Carmen Escuriola-Ettingshausen, et al.
Published: (2023-06-01)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
by: Martin Rodriguez, et al.
Published: (2023-07-01)

In-Silico Characterization of von Willebrand Factor Bound to FVIII
by: Valentina Drago, et al.
Published: (2022-08-01)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
by: Swystun LL, et al.
Published: (2023-03-01)